| For: | Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017; 9(2): 76-91 [PMID: 28289523 DOI: 10.4330/wjc.v9.i2.76] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v9/i2/76.htm |
| Number | Citing Articles |
| 1 |
Mohammed A. Akram, Abdelhamid Khodja, Sarah Dalibalta, Amin F. Majdalawieh. The Role of Lipids in Atherosclerosis: Focus on Molecular Biology Mechanisms and Therapeutic Approaches. Current Medicinal Chemistry 2025; 32(15) doi: 10.2174/0109298673348217241119063941
|
| 2 |
Rahayu Zulkapli, Suhaila Abd Muid, Seok Mui Wang, Hapizah Nawawi. PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells. International Journal of Molecular Sciences 2023; 24(6) doi: 10.3390/ijms24065098
|
| 3 |
Michael J. Chehade, Michael J. Haas, Arshag D. Mooradian. Reframing the High-density Lipoprotein (HDL) Hypothesis in Light of Clinical Trials of Cholesterol Ester Transfer Protein (CETP) Inhibitors. Drugs 2026; 86(7) doi: 10.1007/s40265-026-02338-6
|
| 4 |
Jiqing Li, Jiate Wei, Ping Fu, Jianhua Gu. Identification of novel proteins for coronary artery disease by integrating GWAS data and human plasma proteomes. Heliyon 2024; 10(19) doi: 10.1016/j.heliyon.2024.e38036
|
| 5 |
Tays Troncoso‐Bravo, Valentina Pavez, Pedro Letelier, Javier Del Río, Cristian Anabalón, Hernán F. Peñaloza, Pablo A. González, Susan M. Bueno, Alexis M. Kalergis. Current GMP standards for the large‐scale production of monoclonal antibodies. Bioengineering & Translational Medicine 2026; 11(3) doi: 10.1002/btm2.70121
|
| 6 |
Willemijn A. M. Schonck, Erik S. G. Stroes, G. Kees Hovingh, Laurens F. Reeskamp. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature. Drugs 2024; 84(2) doi: 10.1007/s40265-024-01995-9
|
| 7 |
Bhawneet Chadha, William H. Frishman. Review of the Protective Effects of Statins on Cognition. Cardiology in Review 2021; 29(6) doi: 10.1097/CRD.0000000000000359
|
| 8 |
Manasvi Gupta, Ramyashree Tummala, Raktim K. Ghosh, Colin Blumenthal, Karan Philip, Dhrubajyoti Bandyopadhyay, Hector Ventura, Prakash Deedwania. An update on pharmacotherapies in diabetic dyslipidemia. Progress in Cardiovascular Diseases 2019; 62(4) doi: 10.1016/j.pcad.2019.07.006
|
| 9 |
Yoon kyung Chang, Tae-Jin Song. Management of Dyslipidemia after Stroke. Journal of the Korean Neurological Association 2022; 40(3) doi: 10.17340/jkna.2022.3.1
|
| 10 |
Alexander von Ehr, Ines Derya Steenbuck, Charlotte Häfele, Felix Remmersmann, Tamara A. Vico, Carolin Ehlert, Diana Lindner, Dennis Wolf, Stefan Tholen, Oliver Schilling, Martin Czerny, Dirk Westermann, Ingo Hilgendorf. Experimental evidence on colchicine's mode of action in human carotid artery plaques. Atherosclerosis 2025; 406 doi: 10.1016/j.atherosclerosis.2025.119239
|
| 11 |
Rajeev Chawla, SV Madhu, BM Makkar, Sujoy Ghosh, Banshi Saboo, Sanjay Kalra. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism 2020; 24(1) doi: 10.4103/ijem.IJEM_225_20
|
| 12 |
Daniela Grejtakova, Iveta Boronova, Jarmila Bernasovska, Stefano Bellosta. PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes. Cardiovascular Drugs and Therapy 2025; 39(6) doi: 10.1007/s10557-024-07599-5
|
| 13 |
Anastasia V. Poznyak, Dwaipayan Bharadwaj, Gauri Prasad, Andrey V. Grechko, Margarita A. Sazonova, Alexander N. Orekhov. Anti-Inflammatory Therapy for Atherosclerosis: Focusing on Cytokines. International Journal of Molecular Sciences 2021; 22(13) doi: 10.3390/ijms22137061
|
| 14 |
Roshni S. Patel, Emily M. Scopelliti, Oludamilola Olugbile. The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia. Annals of Pharmacotherapy 2018; 52(10) doi: 10.1177/1060028018771670
|
| 15 |
Hanan B Albackr, Khalid Al Waili, Wael Almahmeed, Mohammad Al Jarallah, Mohammad I Amin, Khalid Alrasadi, Mohammed A. Batais, Turky H. Almigbal, Ali Youssef, Mohammad Alghamdi, Mohammad Al Shehri, Islam Ahmad, Riham A. ElToukhy, Naji Kholaif, Abdulhalim J. Kinsara, Manal Al-Kindi, Nooshin Barzargani, Magdy Hassan, Shamsa Al Suwaidi, Rajesh Rajan, Hani Altaradi, Khalid F Alhabib. The Gulf Achievement of Cholesterol Targets in Out-Patients Study
(GULF ACTION): Design, Rationale, and Preliminary Results. Current Vascular Pharmacology 2023; 21(4) doi: 10.2174/1570161121666230710145604
|
| 16 |
Enrique Gallego-Colon, Aner Daum, Chaim Yosefy. Statins and PCSK9 inhibitors: A new lipid-lowering therapy. European Journal of Pharmacology 2020; 878 doi: 10.1016/j.ejphar.2020.173114
|
| 17 |
Meghan L. Good, Parisa Malekzadeh, Samantha M. Ruff, Shreya Gupta, Amy Copeland, Karel Pacak, Naris Nilubol, Electron Kebebew, Dhaval Patel. Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels. World Journal of Surgery 2020; 44(2) doi: 10.1007/s00268-019-05175-9
|
| 18 |
Thayana A. Cruz, Nicholas R. Larson, Yangjie Wei, Natalia Subelzu, Yaqi Wu, Christian Schöneich, Leda R. Castilho, Charles Russell Middaugh. Characterization of Critical Quality Attributes of an Anti-PCSK9 Monoclonal Antibody. Biologics 2024; 4(3) doi: 10.3390/biologics4030019
|
| 19 |
Miguel García-Villarino, Claudia Lozano-Aida, Lorena Suárez-Gutiérrez, Carmen Lambert, Tomás González-Vidal, Ana Victoria García, Pedro Pujante, Elsa Villa-Fernández, Elías Delgado-Álvarez, Edelmiro Menéndez-Torre, Jessica Ares-Blanco. Use of Lipid-Lowering Treatment in Primary Prevention in Spain (Lipidspain). Journal of Clinical Medicine 2025; 14(17) doi: 10.3390/jcm14176059
|
| 20 |
Kitty Pham, Anwar Mulugeta, Amanda Lumsden, Elina Hyppӧnen. Genetically instrumented LDL‐cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome‐wide association study in the UK Biobank. British Journal of Clinical Pharmacology 2023; 89(10) doi: 10.1111/bcp.15793
|
| 21 |
扬 刘. Application of PCSK9 Inhibitors in Lipid Metabolism and Arteriosclerosis. Advances in Clinical Medicine 2023; 13(08) doi: 10.12677/ACM.2023.1381742
|
| 22 |
Barak Zafrir, Aya Egbaria, Nili Stein, Avishay Elis, Walid Saliba. PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization. Journal of Clinical Lipidology 2021; 15(1) doi: 10.1016/j.jacl.2020.11.004
|
| 23 |
Isis Paez, Yalena Prado, Pía Loren, Carmen G. Ubilla, Nelia Rodríguez, Luis A. Salazar. Cholesterol-Related lncRNAs as Response Predictors of Atorvastatin Treatment in Chilean Hypercholesterolemic Patients: A Pilot Study. Biomedicines 2023; 11(3) doi: 10.3390/biomedicines11030742
|
| 24 |
Nahuel Fernandez Machulsky, Dario Jacobsen, Abi Cardozo Madaf, Antonella Fochi, Maria Eugenia Gomez, Gabriela Berg. Comparison of the Friedewald, Sampson, and Martin Formulas with Direct Homogeneous Assay of Low-Density Lipoprotein Cholesterol in South American Patients. The Journal of Applied Laboratory Medicine 2026; 11(2) doi: 10.1093/jalm/jfaf204
|
| 25 |
Jay Shendure, Gregory M. Findlay, Matthew W. Snyder. Genomic Medicine–Progress, Pitfalls, and Promise. Cell 2019; 177(1) doi: 10.1016/j.cell.2019.02.003
|
| 26 |
Natalie C. Ward, Michael M. Page, Gerald F. Watts. PCSK9 inhibition 2018: riding a new wave of coronary prevention. Clinical Science 2019; 133(2) doi: 10.1042/CS20171300
|
| 27 |
Katrine Bjune, Lene Wierød, Soheil Naderi. Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-34237-6
|
| 28 |
Allison B. Reiss, Neal Shah, Dalia Muhieddine, Juan Zhen, Jennifer Yudkevich, Lora J. Kasselman, Joshua DeLeon. PCSK9 in cholesterol metabolism: from bench to bedside. Clinical Science 2018; 132(11) doi: 10.1042/CS20180190
|
| 29 |
Kaveh Hosseini, Hamidreza Soleimani, Saba Maleki, Amir Nasrollahizadeh, Sima Tayebi, John Nelson, Sean P. Heffron. Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2024; 24(1) doi: 10.1186/s12872-024-04057-w
|
| 30 |
Charles A. German, Michael D. Shapiro. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. BioDrugs 2020; 34(1) doi: 10.1007/s40259-019-00399-6
|
| 31 |
Manik Chhabra, Kota Vidyasagar, Sai Krishna Gudi, Jatin Sharma, Rishabh Sharma, Muhammed Rashid, Jie V. Zhao. Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies. PLOS ONE 2022; 17(7) doi: 10.1371/journal.pone.0269531
|
| 32 |
Dongqi Zhu, Hongyu Qin, Xiaojing Wang, Yuping Jia, Xuejian Wang, Lei Zhang. Discovery of [5,5′‐bibenzo[d][1,3]dioxol]‐6‐substituted amine derivatives as potent proprotein convertase subtilisin/kexin type 9 inhibitors. Chemical Biology & Drug Design 2023; 102(1) doi: 10.1111/cbdd.14264
|
| 33 |
|
| 34 |
Daniela T. Fuller, Andrew T. Grainger, Ani Manichaikul, Weibin Shi. Genetic linkage of oxidative stress with cardiometabolic traits in an intercross derived from hyperlipidemic mouse strains. Atherosclerosis 2020; 293 doi: 10.1016/j.atherosclerosis.2019.11.034
|
| 35 |
Martina Bartolomei, Carlotta Bollati, Jianqiang Li, Anna Arnoldi, Carmen Lammi. Assessment of the Cholesterol-Lowering Effect of MOMAST®: Biochemical and Cellular Studies. Nutrients 2022; 14(3) doi: 10.3390/nu14030493
|
| 36 |
Rida Zainab, Afshan Kaleem, Michał B. Ponczek, Roheena Abdullah, Mehwish Iqtedar, Daniel C. Hoessli, Emilio Gallicchio. Finding inhibitors for PCSK9 using computational methods. PLOS ONE 2021; 16(8) doi: 10.1371/journal.pone.0255523
|
| 37 |
Natalie C. Ward, Gerald F. Watts. PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?. Journal of Clinical Lipidology 2018; 12(4) doi: 10.1016/j.jacl.2018.05.015
|
| 38 |
Zohaib Iqbal, Shaishav Dhage, Jamal Basheer Mohamad, Alaa Abdel-Razik, Rachelle Donn, Rayaz Malik, Jan Hoong Ho, Yifen Liu, Safwaan Adam, Basil Isa, Claudia Stefanutti, Handrean Soran. Efficacy and safety of PCSK9 monoclonal antibodies. Expert Opinion on Drug Safety 2019; 18(12) doi: 10.1080/14740338.2019.1681395
|
| 39 |
Stephen Daniels, Sonia Caprio, Umesh Chaudhari, Garen Manvelian, Marie T. Baccara-Dinet, Aurelie Brunet, Michel Scemama, Virginie Loizeau, Eric Bruckert. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study. Journal of Clinical Lipidology 2020; 14(3) doi: 10.1016/j.jacl.2020.03.001
|
| 40 |
Maria Jesus Valero-Masa, Carlos David Ortiz-Bautista, Javier Castrodeza, Manuel Martinez-Selles. Optimization of Hypercholesterolemia Treatment after Heart Transplant: The Role of PCSK9 Inhibitors. Current Pharmaceutical Design 2024; 30(35) doi: 10.2174/0113816128315228240716183827
|
| 41 |
Małgorzata Bednarska-Makaruk, Agnieszka Ługowska. Cholesterol. 2022; doi: 10.1016/B978-0-323-85857-1.00024-9
|
| 42 |
M. I. Voevoda, V. S. Gurevich, M. V. Ezhov, I. V. Sergienko. Inclisiran – a new era in lipid-lowering therapy. Kardiologiia 2022; 62(6) doi: 10.18087/cardio.2022.6.n2115
|
| 43 |
Levi W. Evans, Blythe Durbin-Johnson, Kristen J. Sutton, Phoebe Yam, Yasmine Y. Bouzid, Eduardo Cervantes, Ellen Bonnel, Charles B. Stephenson, Brian J. Bennett. Specific circulating miRNAs are associated with plasma lipids in a healthy American cohort. Physiological Genomics 2024; 56(7) doi: 10.1152/physiolgenomics.00087.2023
|
| 44 |
Smruti M Besekar, Sangita D Jogdand, Waqar M Naqvi. A Systematic Review of the Randomized Controlled Trials of Gemcabene and Its Therapeutic Uses. Cureus 2023; doi: 10.7759/cureus.36811
|
| 45 |
Miguel García-Villarino, Carmen Lambert, Tomás González-Vidal, Ana Victoria García, Elsa Villa-Fernández, Claudia Lozano-Aida, Lorena Suárez-Gutiérrez, Pedro Pujante, Elías Delgado, Edelmiro Menéndez-Torre, Jessica Ares-Blanco. Lipid Profile Management in Secondary Prevention in Spain: Data from the BDCAP Registry in Spain (LIPIDSPAIN). Journal of Clinical Medicine 2025; 14(17) doi: 10.3390/jcm14176037
|
| 46 |
Gabriela Alexandra Solano Peña, Gabriela Fernanda Acurio Armas, Gabriela Alejandra Díaz Teran, Susana Patricia Palacios Serrano, Andrea Carolina Cobo Reyes, Daniel Albino Pullas Taboada, Gissel Katherine Carvajal Chango. PCSK9 inhibition: a new alternative to reduce cholesterol and prevent atherosclerotic cardiovascular disease. Salud, Ciencia y Tecnología 2023; 3 doi: 10.56294/saludcyt2023587
|
| 47 |
Yoonkyung Chang, Soojeong Eom, Minjeong Kim, Tae-Jin Song. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. Medicina 2023; 59(4) doi: 10.3390/medicina59040776
|
| 48 |
Nadir Ali, David M. Diamond, Sarah M. Rice. Ketogenic. 2023; doi: 10.1016/B978-0-12-821617-0.00016-4
|
| 49 |
Joshua Louis Davies, Yimeng Zhang, Inuri Patabendi, Sudarshan Ramachandran, Jyoti Baharani. Injectable Lipid-Lowering Therapies in Chronic Kidney Disease: Efficacy, Outcomes, Safety and Implementation—A Systematic Review. BioMed 2026; 6(2) doi: 10.3390/biomed6020011
|
| 50 |
Carmen Lammi, Maria Bellumori, Lorenzo Cecchi, Martina Bartolomei, Carlotta Bollati, Maria Lisa Clodoveo, Filomena Corbo, Anna Arnoldi, Nadia Mulinacci. Extra Virgin Olive Oil Phenol Extracts Exert Hypocholesterolemic Effects through the Modulation of the LDLR Pathway: In Vitro and Cellular Mechanism of Action Elucidation. Nutrients 2020; 12(6) doi: 10.3390/nu12061723
|
| 51 |
Chao Luan, Yingxue He, Wen Liu, Yicheng Rong, Jian Gao, Kang Xu, Hui Yu, Yu Hu, Jiaan Zhang, Kun Chen, Wenjie Guo. PCSK9 inhibition interrupts the cross-talk between keratinocytes and macrophages and prevents UVB-induced skin damage. Journal of Biological Chemistry 2023; 299(7) doi: 10.1016/j.jbc.2023.104895
|
| 52 |
Jiali Zhu, Xuemei Zhang, Xiu Chen, Yong Sun, Yaolan Dai, Chang Chen, Tiane Zhang, Zhiyong Yan. Studies on the regulation of lipid metabolism and the mechanism of the aqueous and ethanol extracts of Usnea. Biomedicine & Pharmacotherapy 2017; 94 doi: 10.1016/j.biopha.2017.08.012
|
| 53 |
Lin Jiang, Hui Jiang, Sheng Dai, Ying Chen, Youqiang Song, Clara Sze-Man Tang, Shirley Yin-Yu Pang, Shu-Leong Ho, Binbin Wang, Maria-Mercedes Garcia-Barcelo, Paul Kwong-Hang Tam, Stacey S Cherny, Mulin Jun Li, Pak Chung Sham, Miaoxin Li. Deviation from baseline mutation burden provides powerful and robust rare-variants association test for complex diseases. Nucleic Acids Research 2022; 50(6) doi: 10.1093/nar/gkab1234
|
| 54 |
Ricardo Fontes-Carvalho, Pedro Marques Silva, Elisabete Rodrigues, Francisco Araújo, Cristina Gavina, Jorge Ferreira, João Morais. Practical guide for the use of PCSK9 inhibitors in Portugal. Revista Portuguesa de Cardiologia (English Edition) 2019; 38(6) doi: 10.1016/j.repce.2019.07.004
|
| 55 |
Oluwakemi Ebenezer, Pietro Comoglio, Gane Ka-Shu Wong, Jack A. Tuszynski. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. International Journal of Molecular Sciences 2023; 24(4) doi: 10.3390/ijms24044019
|
| 56 |
Shakir Ahamad, Shahnawaz A. Bhat. Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. Journal of Medicinal Chemistry 2022; 65(23) doi: 10.1021/acs.jmedchem.2c01290
|
| 57 |
Stella Talic, Clara Marquina Hernandez, Richard Ofori-Asenso, Danny Liew, Alice Owen, Marjana Petrova, Sean Lybrand, David Thomson, Jenni Ilomaki, Zanfina Ademi, Ella Zomer. Trends in the Utilization of Lipid-Lowering Medications in Australia: An Analysis of National Pharmacy Claims Data. Current Problems in Cardiology 2022; 47(7) doi: 10.1016/j.cpcardiol.2021.100880
|
| 58 |
Usama Bin Ghaffar. Determinants of Risk Factors Associated with Aortic Atherosclerosis: A Quantitative Study in Forensic Autopsies. Biosciences Biotechnology Research Asia 2024; 21(1) doi: 10.13005/bbra/3211
|
| 59 |
Receptor Endocytosis and Signalling in Health and Disease - Part A. Progress in Molecular Biology and Translational Science 2023; 194 doi: 10.1016/bs.pmbts.2022.09.010
|
| 60 |
Marion Laudette, Malin Lindbom, Muhammad Arif, Mathieu Cinato, Mario Ruiz, Stephen Doran, Azra Miljanovic, Mikael Rutberg, Linda Andersson, Martina Klevstig, Marcus Henricsson, Per-Olof Bergh, Entela Bollano, Nay Aung, J Gustav Smith, Marc Pilon, Tuulia Hyötyläinen, Matej Orešič, Rosie Perkins, Adil Mardinoglu, Malin C Levin, Jan Borén. Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function. Cardiovascular Research 2023; 119(7) doi: 10.1093/cvr/cvad041
|
| 61 |
Chao Zhao, Nuan Wang, Dayong Shen, Laiyun Zhu, Guofang Chen. Knowledge, Attitudes, and Practices Regarding PCSK9 Inhibitors Among Healthcare Professionals: Exploring Behavioral Pathways and the Intermediary Role of Attitude. Journal of Multidisciplinary Healthcare 2026; doi: 10.2147/JMDH.S590436
|
| 62 |
Huan Zhu, Zhiqin Zhang, Lihui Zhang, Jiangying Cao, Lei Zhang. Discovery of Novel PCSK9‐LDLR PPI Inhibitors by a Structural Modification Approach. Drug Development Research 2026; 87(5) doi: 10.1002/ddr.70352
|
| 63 |
Soumya Krishnamoorthy, S. Manjunatha, Deepa Damayanthi, P.N. Sylaja, Srinivas Gopala. Multiple facets of HDLs as modifiable risk factors in stroke—the good, the bad, and the ugly. Journal of Lipid Research 2025; 66(9) doi: 10.1016/j.jlr.2025.100879
|
| 64 |
Abhinav Ahuja, Sachin Agrawal, Sourya Acharya, Venkat Reddy, Nitish Batra. Strategies for Cardiovascular Disease Prevention in Type 1 Diabetes: A Comprehensive Review. Cureus 2024; doi: 10.7759/cureus.66420
|
| 65 |
Camille B. Carroll, Richard K.H. Wyse. Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress. Journal of Parkinson’s Disease 2017; 7(4) doi: 10.3233/JPD-171203
|
| 66 |
Hideyuki Torikai, Mei-Hua Chen, Li Jin, Jiang He, John F. Angle, Weibin Shi. Atherogenesis in Apoe−/− and Ldlr−/− Mice with a Genetically Resistant Background. Cells 2023; 12(9) doi: 10.3390/cells12091255
|
| 67 |
Caleb Nunes, Amelia Kramer, Lisa R. Volpatti. Emerging drug delivery strategies for local immunomodulation in atherosclerosis. Journal of Controlled Release 2025; 388 doi: 10.1016/j.jconrel.2025.114261
|
| 68 |
Benjamin J. Tombling, Conan K. Wang, David J. Craik. EGF‐like and Other Disulfide‐rich Microdomains as Therapeutic Scaffolds. Angewandte Chemie International Edition 2020; 59(28) doi: 10.1002/anie.201913809
|
| 69 |
Mohammad Alkhalil. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. Current Drug Metabolism 2019; 20(1) doi: 10.2174/1389200219666180816141827
|
| 70 |
Manoj Mouli, Gagana H P, Kavya B L, Divya R, Gagana K M, Goutham H G, Yunus Pasha. Ischemia Heart Disease: Current Diagnosis, Treatment Methods, and Genetic Research.. Hacettepe University Journal of the Faculty of Pharmacy 2024; 44(4) doi: 10.52794/hujpharm.1498649
|
| 71 |
Mohamed Toufic El Hussein, Aditi Sharma, Komal Parmar, Krupa Shelat. Pharmacotherapeutics for dyslipidemia management. The Nurse Practitioner 2023; 48(6) doi: 10.1097/01.NPR.0000000000000059
|
| 72 |
Neelakandan Annamalai Ramalakshmi, Muthu Kumar Thirunavukkarasu, Fayaz Shaik, Krishna Navami, Rajanikant Golgodu Krishnamurthy. AI-assisted computational screening and docking simulation prioritize marine natural products for small-molecule PCSK9 inhibition. Current Research in Translational Medicine 2025; 73(2) doi: 10.1016/j.retram.2025.103498
|
| 73 |
Esther Torres, Marian Goicoechea, Andrés Hernández, María L. Rodríguez Ferrero, Ana García, Nicolás Macías, Fernando Anaya. Efficacy of Evolocumab vs low‐density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01). Journal of Clinical Apheresis 2020; 35(1) doi: 10.1002/jca.21752
|
| 74 |
Donatella Zodda, Rosario Giammona, Silvia Schifilliti. Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy 2018; 6(1) doi: 10.3390/pharmacy6010010
|
| 75 |
Tingting Yuan, Yi Zhong, Yingge Wang, Ting Zhang, Rui Lu, Minya Zhou, Yaoyao Lu, Kunning Yan, Yajie Chen, Zhehui Hu, Jingyan Liang, Jianglin Fan, Yong Cheng. Generation of hyperlipidemic rabbit models using multiple sgRNAs targeted CRISPR/Cas9 gene editing system. Lipids in Health and Disease 2019; 18(1) doi: 10.1186/s12944-019-1013-8
|
| 76 |
Rafael Campo. Estudios clínicos con inhibidores de la PCSK9. Revista Colombiana de Cardiología 2017; 24 doi: 10.1016/j.rccar.2017.08.019
|
| 77 |
Carmen Lammi, Carlotta Bollati, Davide Lecca, Maria Pia Abbracchio, Anna Arnoldi. Lupin Peptide T9 (GQEQSHQDEGVIVR) Modulates the Mutant PCSK9D374Y Pathway: in vitro Characterization of its Dual Hypocholesterolemic Behavior. Nutrients 2019; 11(7) doi: 10.3390/nu11071665
|
| 78 |
Nivas Shyamala, Kishore Kumar Gundapaneni, Rajesh Kumar Galimudi, Mohini Aiyengar Tupurani, Chiranjeevi Padala, Kaushik Puranam, Keerthi Kupsal, Ramanjaneyulu Kummari, Srilatha Reddy Gantala, Krishna Reddy Nallamala, Sanjib K. Sahu, Surekha Rani Hanumanth. PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients. The Journal of Gene Medicine 2021; 23(8) doi: 10.1002/jgm.3346
|
| 79 |
Elena Domingo, Patrice Marques, Vera Francisco, Laura Piqueras, Maria-Jesus Sanz. Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?. Pharmacological Research 2024; 200 doi: 10.1016/j.phrs.2024.107058
|
| 80 |
Sonia Singh, Manas Kumar Jha. Review on PCSK9: A Pertinent Therapeutic Target in Cardiovascular Disease. Current Bioactive Compounds 2024; 20(1) doi: 10.2174/0115734072270060230921093431
|
| 81 |
Olivia M. Kim, Tatyana K. Givens, Emily G. Tang, Jennifer J. Schimmer, Tanya Ramsey, Kayla Boyd, Thomas Delate. Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use. Journal of Cardiovascular Pharmacology 2023; 81(5) doi: 10.1097/FJC.0000000000001404
|
| 82 |
Gbolahan Olatunji, Emmanuel Kokori, Ismaila Ajayi Yusuf, Olumide Akinmoju, Emmanuel Egbunu, Ifeanyichukwu Muogbo, Kaleb Lema, Sai Gutham Kanagala, Samuel Owolabi, Muili Abdulbasit, Nicholas Aderinto. Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials. Current Problems in Cardiology 2024; 49(4) doi: 10.1016/j.cpcardiol.2024.102419
|
| 83 |
Alisha Aman, Eric A. W. Slob, Joey Ward, Breda Cullen, Nicholas Graham, Donald M. Lyall, Naveed Sattar, Rona J. Strawbridge, Toni-Kim Clarke. Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization. PLOS ONE 2022; 17(12) doi: 10.1371/journal.pone.0279381
|
| 84 |
Joyson J. Karakunnel, Nam Bui, Latha Palaniappan, Keith T. Schmidt, Kenneth W. Mahaffey, Briggs Morrison, William D. Figg, Shivaani Kummar. Reviewing the role of healthy volunteer studies in drug development. Journal of Translational Medicine 2018; 16(1) doi: 10.1186/s12967-018-1710-5
|
| 85 |
V. V. Ryabov, Ya. V. Alekseeva, A. E. Gombozhapova, Ya. V. Sokolova, R. S. Karpov. Atherosclerosis. Macrophages. Viral infections. The Siberian Journal of Clinical and Experimental Medicine 2021; 36(2) doi: 10.29001/2073-8552-2021-36-2-14-22
|
| 86 |
Natalie C. Ward, Gerald F. Watts. Therapeutic Lipidology. Contemporary Cardiology 2021; doi: 10.1007/978-3-030-56514-5_33
|
| 87 |
Ajay K. Shukla, Rekha Mehani. Safety and efficacy of alirocumab. Journal of Family Medicine and Primary Care 2019; 8(7) doi: 10.4103/jfmpc.jfmpc_406_19
|
| 88 |
Benjamin J. Tombling, Conan K. Wang, David J. Craik. EGF‐artige und andere disulfidreiche Mikrodomänen als therapeutische Molekülgerüste. Angewandte Chemie 2020; 132(28) doi: 10.1002/ange.201913809
|
| 89 |
Radhwan Abdul Kareem, Hayder Naji Sameer, Zainab H. Athab, Mohaned Adil, Ahmed Yaseen, Omer Qutaiba B. Allela. Review: natural compounds as PCSK9 inhibitors for antiviral therapy. Archives of Microbiology 2026; 208(9) doi: 10.1007/s00203-026-05006-1
|
| 90 |
Rajinderpal Singh, Sohbat Kaur Chandi, Seerat Sran, Smriti K Aulakh, Gurkamal Singh Nijjar, Kanwarmandeep Singh, Sumerjit Singh, FNU Tanvir, Yasmeen Kaur, Ajay Pal Singh Sandhu. Emerging Therapeutic Strategies in Cardiovascular Diseases. Cureus 2024; doi: 10.7759/cureus.64388
|
| 91 |
Niki Katsiki, Dimitri P Mikhailidis, Maciej Banach. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opinion on Pharmacotherapy 2019; 20(16) doi: 10.1080/14656566.2019.1649394
|
| 92 |
Michele Scognamiglio, Dario Costa, Antonio Sorriento, Claudio Napoli. Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. Current Pharmaceutical Design 2019; 25(1) doi: 10.2174/1381612825666190130101108
|
| 93 |
Dean L. Kellogg, Susan Fisher-Hoch, Joseph B. McCormick, Anand Prasad. Searching for the Genetic Determinants of Peripheral Arterial Disease. Cardiology in Review 2019; 27(3) doi: 10.1097/CRD.0000000000000231
|
| 94 |
Dieter K. Lam, Patricia R. Feliciano, Amena Arif, Tanggis Bohnuud, Thomas P. Fernandez, Jason M. Gehrke, Phil Grayson, Kin D. Lee, Manuel A. Ortega, Courtney Sawyer, Noah D. Schwaegerle, Leila Peraro, Lauren Young, Seung-Joo Lee, Giuseppe Ciaramella, Nicole M. Gaudelli. Improved cytosine base editors generated from TadA variants. Nature Biotechnology 2023; 41(5) doi: 10.1038/s41587-022-01611-9
|
| 95 |
Farzana Akter Munny, Abir Hasan Pranto, Shimanta Paul, Md. Aminul Haque, Rashna Sharmin, Sharifa Sultana, Md. Alamgir Hossain, Md. Rabiul Islam. Reduced Serum Soluble L‐Selectin Levels but Not PCSK9 May Be Associated With Generalized Anxiety Disorder: A Case–Control Study. Journal of Clinical Laboratory Analysis 2026; 40(1) doi: 10.1002/jcla.70144
|
| 96 |
Prabhakar Dorairaj, Hemnath C, Malini Sreyan, Ramadesikan Veeraraghavan Kuppuswamy, Perumalraja R, Vijayakumar PG. Comparison of Various Low Density Lipoprotein Cholesterol Calculators: Is It Time for the Friedewald Equation to Go in India?. Journal of The Association of Physicians of India 2024; 72(9) doi: 10.59556/japi.72.0645
|
| 97 |
PRIYANKA VENUNGOPAL, KARTHIKEYAN BALAKRISHNAN, DAMAL KANDADAI SRIRAM, MELVIN GEORGE. INCLISIRAN (LEQVIO): A FIRST-IN-CLASS SMALL INTERFERING RNA THERAPEUTIC DRUG APPROVED BY FDA FOR TREATING PRIMARY HYPERCHOLESTEROLEMIA OR DYSLIPIDEMIA. Asian Journal of Pharmaceutical and Clinical Research 2022; doi: 10.22159/ajpcr.2022.v15i12.46054
|
| 98 |
Mengyu Sun, Qi Wang, Li Wu, Yanjie Zhang, Jinsong Ren, Xiaogang Qu. Piezoelectricity-Potentiated Bioorthogonal Catalysis Disrupts Cholesterol Metabolism for Tumor Immunotherapy. ACS Nano 2025; 19(46) doi: 10.1021/acsnano.5c14098
|
| 99 |
X. Pintó, I. Sarasa. Nuevas perspectivas en el tratamiento de la hipercolesterolemia desde la disponibilidad de los inhibidores de la proteína PCSK9. Hipertensión y Riesgo Vascular 2019; 36(4) doi: 10.1016/j.hipert.2019.05.005
|
| 100 |
Junying Miao, Xiaoling Zang, Xiaoling Cui, Jun Zhang. Autophagy: Biology and Diseases. Advances in Experimental Medicine and Biology 2020; 1207 doi: 10.1007/978-981-15-4272-5_18
|
| 101 |
Roberto Garcia, Jaime Burkle. New and Future Parenteral Therapies for the Management of Lipid Disorders. Archives of Medical Research 2018; 49(8) doi: 10.1016/j.arcmed.2019.01.001
|
| 102 |
Alexander D. Mazura, Claus U. Pietrzik. Endocrine Regulation of Microvascular Receptor—Mediated Transcytosis and Its Therapeutic Opportunities: Insights by PCSK9—Mediated Regulation. Pharmaceutics 2023; 15(4) doi: 10.3390/pharmaceutics15041268
|
| 103 |
Akram N. Salah, Amr H. Hashem, Mohamed Bakr Zaki, Ahmed I. Abulsoud, Asmaa M. Atta, Wagiha S. Elkalla, Hebatallah Ahmed Mohamed Moustafa, Walaa A. El‐Dakroury, Fatma Sa'eed El‐Tokhy, Jasmine A. ElBoghdady, Nehal I. Rizk, Sherif S. Abdel Mageed, Osama A. Mohammed, Mustafa Ahmed Abdel‐Reheim, Huda O. Alghamdi, Ahmed S. Doghish. Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management. Journal of Biochemical and Molecular Toxicology 2025; 39(2) doi: 10.1002/jbt.70163
|
| 104 |
Chanisa Thonusin, Nattayaporn Apaijai, Thidarat Jaiwongkam, Sasiwan Kerdphoo, Busarin Arunsak, Patchareeya Amput, Siripong Palee, Wasana Pratchayasakul, Nipon Chattipakorn, Siriporn C. Chattipakorn. The comparative effects of high dose atorvastatin and proprotein convertase subtilisin/kexin type 9 inhibitor on the mitochondria of oxidative muscle fibers in obese-insulin resistant female rats. Toxicology and Applied Pharmacology 2019; 382 doi: 10.1016/j.taap.2019.114741
|
| 105 |
Nikolaos Velidakis, Panagiotis Stachteas, Evangelia Gkougkoudi, Christodoulos Papadopoulos, Nikolaos P. E. Kadoglou. Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease—A Narrative Clinical Review. Pharmaceuticals 2024; 17(5) doi: 10.3390/ph17050568
|
| 106 |
Veronika A. Myasoedova, Alessio L. Ravani, Beatrice Frigerio, Vincenza Valerio, Donato Moschetta, Paola Songia, Paolo Poggio. Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments. Pharmacological Research 2018; 136 doi: 10.1016/j.phrs.2018.08.020
|
| 107 |
Philip Branigan, Y. V Duong, Ammar Y Abdulfattah, Jacob Sabu, Mary Mallappallil, Sabu John. Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies. Cureus 2024; doi: 10.7759/cureus.60877
|
| 108 |
Pilar Hoyos, Vittorio Pace, Andrés R. Alcántara. Biocatalyzed Synthesis of Statins: A Sustainable Strategy for the Preparation of Valuable Drugs. Catalysts 2019; 9(3) doi: 10.3390/catal9030260
|
| 109 |
Xiaoming Jia, Mahmoud Al Rifai, Anum Saeed, Christie M Ballantyne, Salim S Virani. PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vascular Health and Risk Management 2022; doi: 10.2147/VHRM.S275739
|
| 110 |
Hamideh Amirfakhryan. Vaccination against atherosclerosis: An overview. Hellenic Journal of Cardiology 2020; 61(2) doi: 10.1016/j.hjc.2019.07.003
|
| 111 |
Isabella Giacomini, Federico Gianfanti, Maria Andrea Desbats, Genny Orso, Massimiliano Berretta, Tommaso Prayer-Galetti, Eugenio Ragazzi, Veronica Cocetta. Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.682911
|
| 112 |
Lameeya Murtaza Bandukwala, Daniel Curley, Alkis Bontinis, Vangelis Bontinis, Joseph Shalhoub. PCSK9 Inhibitors in Peripheral Arterial Disease: A Systematic Review. Annals of Vascular Surgery 2026; 128 doi: 10.1016/j.avsg.2026.03.025
|
| 113 |
Velimir Altabas, Lora Stanka Kirigin Biloš. The Role of Endothelial Progenitor Cells in Atherosclerosis and Impact of Anti-Lipemic Treatments on Endothelial Repair. International Journal of Molecular Sciences 2022; 23(5) doi: 10.3390/ijms23052663
|
| 114 |
Michael A. Hicks, Claire Y.C. Hou, Arya Iranmehr, Krisztina Marosi, Ewen Kirkness. Target discovery using biobanks and human genetics. Drug Discovery Today 2020; 25(2) doi: 10.1016/j.drudis.2019.09.014
|
| 115 |
Mario Crisci, Federica Ilardi, Rachele Manzo, Felice Gragnano, Roberta Paolillo, Giuseppe Giugliano, Orlando Piro, Emanuele Cigala, Ida Monteforte, Veronica D'Oria, Enzo Venga, Alessandra Marotta, Angela Salvato, Paolo Calabrò, Giovanni Esposito, Emilio Di Lorenzo, Marisa De Feo. Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2026; doi: 10.1016/j.numecd.2026.104728
|
| 116 |
James Milner, Andreia Cunha, Carlota Gamboa-Cruz, Julie Reis, Márcia Campos, Natália António. Recent major advances in cardiovascular pharmacotherapy. European Journal of Clinical Pharmacology 2018; 74(7) doi: 10.1007/s00228-018-2453-1
|
| 117 |
Yajnavalka Banerjee, Anca Pantea Stoian, Arrigo Francesco Giuseppe Cicero, Federica Fogacci, Dragana Nikolic, Alexandros Sachinidis, Ali A. Rizvi, Andrej Janez, Manfredi Rizzo. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opinion on Drug Safety 2022; 21(1) doi: 10.1080/14740338.2022.1988568
|
| 118 |
Aisha Siddiq A, Asha Martin. Crocetin exerts hypocholesterolemic effect by inducing LDLR and inhibiting PCSK9 and Sortilin in HepG2 cells. Nutrition Research 2022; 98 doi: 10.1016/j.nutres.2021.08.005
|
| 119 |
Marko Kumric, Hrvoje Urlic, Josko Bozic, Marino Vilovic, Tina Ticinovic Kurir, Duska Glavas, Dino Miric, Jaksa Zanchi, Anteo Bradaric-Slujo, Mislav Lozo, Josip A. Borovac. Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside. International Journal of Molecular Sciences 2023; 24(9) doi: 10.3390/ijms24098062
|
| 120 |
Amy Elizabeth Morgan, Mark Tomás Mc Auley. Cholesterol Homeostasis: An In Silico Investigation into How Aging Disrupts Its Key Hepatic Regulatory Mechanisms. Biology 2020; 9(10) doi: 10.3390/biology9100314
|
| 121 |
Zi-Tong Huang, Wen-Hui Zhang, Dong-Ze Wang, Ya-Juan Zhang, Yi-Bing Duan, Xin-Yang He, Yang-Xin Gao, Zhuo-Nan Jia, Qian Xu. Major adverse events associated with lipid reduction in inclisiran: a pharmacovigilance research of the FAERS database. Expert Opinion on Drug Safety 2026; 25(3) doi: 10.1080/14740338.2024.2446407
|
| 122 |
Henry T. Greely. Human Germline Genome Editing: An Assessment. The CRISPR Journal 2019; 2(5) doi: 10.1089/crispr.2019.0038
|
| 123 |
Truong Phuong Kim, Lao Thuan Duc, Huyen Le Thuy Ai. The Major Molecular Causes of Familial Hypercholesterolemia. Asian Journal of Pharmaceutical Research and Health Care 2018; 10(2) doi: 10.18311/ajprhc/2018/20031
|
| 124 |
Penelope Poppy Janpen Sucharitkul, Keely Louise Jones, David Julian Ashbridge Scott, Marc Aaron Bailey. Lipid Optimization in Lower Extremity Peripheral Arterial Disease. Annals of Vascular Surgery 2021; 76 doi: 10.1016/j.avsg.2021.03.055
|
| 125 |
Danial Khayatan, Kimia Zare, Maryam Khanahmadi, Saeideh Momtaz, Alexandra E. Butler, Tannaz Jamialahmadi, Wael Almahmeed, Amir Hossein Abdolghaffari, Amirhossein Sahebkar. The role of natural products as PCSK9 modulators: A review. Phytotherapy Research 2024; 38(8) doi: 10.1002/ptr.8260
|
| 126 |
Vesna Vucic, Romana Masnikosa. Reference Module in Food Science. 2017; doi: 10.1016/B978-0-08-100596-5.21339-5
|
| 127 |
Ching-Hui Sia, Oliver Simon, Poay-Huan Loh, Kian Keong Poh. Atherosclerotic cardiovascular disease landscape in Singapore. Frontiers in Cardiovascular Medicine 2024; 11 doi: 10.3389/fcvm.2024.1342698
|
| 128 |
Carmen Lammi, Nadia Mulinacci, Lorenzo Cecchi, Maria Bellumori, Carlotta Bollati, Martina Bartolomei, Carlo Franchini, Maria Lisa Clodoveo, Filomena Corbo, Anna Arnoldi. Virgin Olive Oil Extracts Reduce Oxidative Stress and Modulate Cholesterol Metabolism: Comparison between Oils Obtained with Traditional and Innovative Processes. Antioxidants 2020; 9(9) doi: 10.3390/antiox9090798
|
| 129 |
Iveta Merćep, Dominik Strikić, Ana Marija Slišković, Željko Reiner. New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review. Pharmaceuticals 2022; 15(7) doi: 10.3390/ph15070839
|
| 130 |
Poobalan Naidoo, Rashem Mothilal, Dirk Jacobus Blom. Therapeutic Management of Dyslipidemia Patients at Very High Cardiovascular Risk (CARDIO TRACK): Protocol for the Observational Registry Study. JMIR Research Protocols 2018; 7(6) doi: 10.2196/resprot.9248
|
| 131 |
Kerstin Stemmer, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp, Timo D. Müller. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. Advanced Drug Delivery Reviews 2020; 159 doi: 10.1016/j.addr.2020.05.008
|
| 132 |
Rabia Shahid, Shaili S Naik, Shivana Ramphall, Swarnima Rijal, Vishakh Prakash, Heba Ekladios, Jiya Mulayamkuzhiyil Saju, Naishal Mandal, Nang I Kham, Pousette Hamid. Neurocognitive Impairment in Cardiovascular Disease Patients Taking Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Systematic Review. Cureus 2022; doi: 10.7759/cureus.30942
|
| 133 |
Anindya Amanda Damayanti, Riana Rahmawati, Amany Taqiyyah Wardhani, Raisa Kamila Putri, Zavia Putri Salsabila. Proceedings of the 3rd International Conference on Cardiovascular Diseases (ICCvD 2021). 2023; doi: 10.2991/978-94-6463-048-0_33
|
| 134 |
Son Min-Gyung, Pisey Pel, Chae-Yeong An, Chan-Woong Park, Sae Hyun Lee, Tae-Jin Yang, Young-Won Chin. Chemical constituents from the roots of Cynanchum wilfordii with PCSK9 secretion inhibitory activities. Phytochemistry 2024; 226 doi: 10.1016/j.phytochem.2024.114205
|
| 135 |
Satyavir Yadav, Jitendra Pal Singh Sawhney. Treatment of dyslipidemia in acute coronary syndrome. Indian Heart Journal 2024; 76 doi: 10.1016/j.ihj.2024.01.011
|
| 136 |
Ivo P. van de Peppel, Anna Bertolini, Theo H. van Dijk, Albert K. Groen, Johan W. Jonker, Henkjan J. Verkade. Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice. Journal of Lipid Research 2019; 60(9) doi: 10.1194/jlr.M094607
|
| 137 |
Aditi Sharma, Chakshu Sharma, Lalit Sharma, Pranay Wal, Preeti Mishra, Nitin Sachdeva, Shivam Yadav, Celia Vargas De-La Cruz, Sandeep Arora, Vetriselvan Subramaniyan, Ravi Rawat, Tapan Behl, Mukesh Nandave. Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis. Canadian Journal of Physiology and Pharmacology 2024; 102(5) doi: 10.1139/cjpp-2023-0259
|
| 138 |
Shuo Geng, Yajun Wu, Liwu Li. Immune Homeostasis. Methods in Molecular Biology 2024; 2782 doi: 10.1007/978-1-0716-3754-8_2
|
| 139 |
Maureen Sampson, Anna Wolska, Justine Cole, Rafael Zubirán, James D. Otvos, Jeff W. Meeusen, Leslie J. Donato, Allan S. Jaffe, Alan T. Remaley. Accuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations. Biomedicines 2022; 10(12) doi: 10.3390/biomedicines10123156
|
| 140 |
Giovanni Ciccarelli, Saverio D’Elia, Michele De Paulis, Paolo Golino, Giovanni Cimmino. Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. Diseases 2018; 6(1) doi: 10.3390/diseases6010022
|
| 141 |
Vishal Kumar, Chitra Vellapandian. Unraveling the Nexus Between Ambient Air Pollutants and Cardiovascular Morbidity: Mechanistic Insights and Therapeutic Horizons. Cureus 2024; doi: 10.7759/cureus.68650
|
| 142 |
Pratiksha Jamadade, Neh Nupur, Krushna Ch Maharana, Sanjiv Singh. Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives. Current Atherosclerosis Reports 2024; 26(10) doi: 10.1007/s11883-024-01228-0
|
| 143 |
Yanqiang Zou, Zhang Chen, Xi Zhang, Jizhang Yu, Heng Xu, Jikai Cui, Yuan Li, Yuqing Niu, Cheng Zhou, Jiahong Xia, Jie Wu. Targeting PCSK9 Ameliorates Graft Vascular Disease in Mice by Inhibiting NLRP3 Inflammasome Activation in Vascular Smooth Muscle Cells. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.894789
|
| 144 |
Jitendra Gupta, Reena Gupta. PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders:
Heralding a New Therapeutic Era and Their Future Perspectives. Current Molecular Pharmacology 2023; 16(8) doi: 10.2174/1874467216666221202144813
|
| 145 |
Guhan R Venkataraman, Manuel A Rivas. Rare and common variant discovery in complex disease: the IBD case study. Human Molecular Genetics 2019; 28(R2) doi: 10.1093/hmg/ddz189
|
| 146 |
Daniel Steffens, Peter Bramlage, Céline Scheeff, Mario Kasner, Adel Hassanein, Julian Friebel, Ursula Rauch-Kröhnert. PCSK9 inhibitors and cardiovascular outcomes. Expert Opinion on Biological Therapy 2020; 20(1) doi: 10.1080/14712598.2020.1677604
|
| 147 |
Sarah J. Beecroft, Phillipa J. Lamont, Samantha Edwards, Hayley Goullée, Mark R. Davis, Nigel G. Laing, Gianina Ravenscroft. The Impact of Next-Generation Sequencing on the Diagnosis, Treatment, and Prevention of Hereditary Neuromuscular Disorders. Molecular Diagnosis & Therapy 2020; 24(6) doi: 10.1007/s40291-020-00495-2
|
| 148 |
Harry Aldworth, Nigel M. Hooper. Post-translational regulation of the low-density lipoprotein receptor provides new targets for cholesterol regulation. Biochemical Society Transactions 2024; 52(1) doi: 10.1042/BST20230918
|
| 149 |
Yousuf Zafar, Yasar Sattar, Waqas Ullah, Sohaib Roomi, Mamoon-Ur- Rashid, Muhammad Shayan Khan, Laura Schmidt. Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis. Journal of Community Hospital Internal Medicine Perspectives 2020; 10(1) doi: 10.1080/20009666.2019.1710952
|
| 150 |
Gopal Chandra Ghosh, Dhrubajyoti Bandyopadhyay, Raktim K. Ghosh, Samhati Mondal, Eyal Herzog. Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9. The American Journal of Cardiology 2018; 122(7) doi: 10.1016/j.amjcard.2018.06.023
|
| 151 |
Annemarie Wolf, Hanna Sarah Kutsche, Rolf Schreckenberg, Martin Weber, Ling Li, Susanne Rohrbach, Rainer Schulz, Klaus-Dieter Schlüter. Autocrine effects of PCSK9 on cardiomyocytes. Basic Research in Cardiology 2020; 115(6) doi: 10.1007/s00395-020-00824-w
|
| 152 |
Lakshmi Lavanya Reddy, Swarup A. V. Shah, Chandrashekhar K. Ponde, Jamshed J. Dalal, Raj G. Jatale, Reeta J. Dalal, Rajesh M. Rajani, Sudhir K. Pillai, Chander V. Vanjani, Tester F. Ashavaid. Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India. Journal of Human Genetics 2021; 66(10) doi: 10.1038/s10038-021-00924-y
|
| 153 |
Busarin Arunsak, Wasana Pratchayasakul, Patchareeya Amput, Kenneth Chattipakorn, Theetouch Tosukhowong, Sasiwan Kerdphoo, Thidarat Jaiwongkum, Chanisa Thonusin, Siripong Palee, Nipon Chattipakorn, Siriporn C Chattipakorn. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats. Archives of Biochemistry and Biophysics 2020; 689 doi: 10.1016/j.abb.2020.108470
|
| 154 |
Emma M. O’Connell, Falk W. Lohoff. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders. Frontiers in Neuroscience 2020; 14 doi: 10.3389/fnins.2020.00609
|
| 155 |
Adi prasad Bodapati, Ayesha Hanif, Donatus K Okafor, Gitika Katyal, Gursharan Kaur, Hafsa Ashraf, Safeera Khan. PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis. Cureus 2023; doi: 10.7759/cureus.46605
|
| 156 |
Roberto Cemin, Simona Casablanca, Davide Ermacora, Massimo Daves. The Importance of Being Aware of Intrinsic Methods’ Limitation in Low-Density Lipoprotein Cholesterol Determination to Correctly Identify Cardiovascular Risk: Is Direct Determination Obtained with the Roche System Systematically Overestimating LDL in Very High-Risk Patients with Triglycerides Concentration of Less than (<2.25 mmol/L)?. Journal of Clinical Medicine 2023; 12(13) doi: 10.3390/jcm12134422
|
| 157 |
BinBin Zheng-Lin, Alberto Ortiz. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs 2018; 78(2) doi: 10.1007/s40265-017-0858-2
|
| 158 |
Anna Gluba-Brzózka, Beata Franczyk, Magdalena Rysz-Górzyńska, Janusz Ławiński, Jacek Rysz. Emerging Anti-Atherosclerotic Therapies. International Journal of Molecular Sciences 2021; 22(22) doi: 10.3390/ijms222212109
|
| 159 |
Vishnu Priya Pulipati, Michael H. Davidson. Recent advances and emerging therapies in management of dyslipidemias. Trends in Cardiovascular Medicine 2021; 31(7) doi: 10.1016/j.tcm.2020.08.007
|
| 160 |
Constantine E Kosmas, Andreas Skavdis, Andreas Sourlas, Evangelia J Papakonstantinou, Edilberto Peña Genao, Rogers Echavarria Uceta, Eliscer Guzman. <p>Safety and Tolerability of PCSK9 Inhibitors: Current Insights</p>. Clinical Pharmacology: Advances and Applications 2020; doi: 10.2147/CPAA.S288831
|
| 161 |
Hui-Fang Chiu, You-Cheng Shen, Kamesh Venkatakrishnan, Chin-Kun Wang. Popular functional foods and nutraceuticals with lipid lowering activity and in relation to cardiovascular disease, dyslipidemia, and related complications: an overview. Journal of Food Bioactives 2018; doi: 10.31665/JFB.2018.2137
|
| 162 |
Ya-Nan Qiao, Yan-Li Zou, Shou-Dong Guo. Low-density lipoprotein particles in atherosclerosis. Frontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.931931
|
| 163 |
Shengtao Xu, Shanshan Luo, Zheying Zhu, Jinyi Xu. Small molecules as inhibitors of PCSK9: Current status and future challenges. European Journal of Medicinal Chemistry 2019; 162 doi: 10.1016/j.ejmech.2018.11.011
|
| 164 |
Maureen Sampson, Clarence Ling, Qian Sun, Roa Harb, Mohmed Ashmaig, Russell Warnick, Amar Sethi, James K. Fleming, James D. Otvos, Jeff W. Meeusen, Sarah R. Delaney, Allan S. Jaffe, Robert Shamburek, Marcelo Amar, Alan T. Remaley. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiology 2020; 5(5) doi: 10.1001/jamacardio.2020.0013
|
| 165 |
Wei Yin, Mark Rogge. Targeting RNA: A Transformative Therapeutic Strategy. Clinical and Translational Science 2019; 12(2) doi: 10.1111/cts.12624
|
| 166 |
Leigh Goedeke, Alberto Canfrán-Duque, Noemi Rotllan, Balkrishna Chaube, Bonne M. Thompson, Richard G. Lee, Gary W. Cline, Jeffrey G. McDonald, Gerald I. Shulman, Miguel A. Lasunción, Yajaira Suárez, Carlos Fernández-Hernando. MMAB promotes negative feedback control of cholesterol homeostasis. Nature Communications 2021; 12(1) doi: 10.1038/s41467-021-26787-7
|
| 167 |
Thanyatorn Chantivas, Prin Vathesatogkit, Anchalee Chittamma, Nisakron Thongmung, Martin H Kroll, Pornpen Srisawasdi. Calculated small-dense and large-buoyant low-density lipoprotein-cholesterol and their ratio in predicting coronary artery disease risk: A cohort study in Thailand. Clinical Biochemistry 2025; 140 doi: 10.1016/j.clinbiochem.2025.111018
|
| 168 |
Nurjannatul Naim Kamaruddin, Nor Azwin Hajri, Yosie Andriani, Aina Farahiyah Abdul Manan, Tengku Sifzizul Tengku Muhammad, Habsah Mohamad. Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats. Molecules 2021; 26(16) doi: 10.3390/molecules26165094
|
| 169 |
Jin Sook Yoon, Don O. Kikkawa. Thyroid eye disease. Taiwan Journal of Ophthalmology 2022; 12(1) doi: 10.4103/tjo.tjo_51_21
|
| 170 |
Roberto CEMIN, Simona CASABLANCA, Davide ERMACORA, Massimo DAVES. Misurazione diretta del colesterolo-LDL e sue possibili conseguenze sulla terapia farmacologica. La Rivista Italiana della Medicina di Laboratorio 2024; 19(4) doi: 10.23736/S1825-859X.23.00217-7
|
| 171 |
Saverio Muscoli, Mihaela Ifrim, Massimo Russo, Francesco Candido, Angela Sanseviero, Marialucia Milite, Marco Di Luozzo, Massimo Marchei, Giuseppe Sangiorgi. Current Options and Future Perspectives in the Treatment of Dyslipidemia. Journal of Clinical Medicine 2022; 11(16) doi: 10.3390/jcm11164716
|
| 172 |
Marion Mussbacher, Manuel Salzmann, Barbara Haigl, José Basílio, Bernhard Hochreiter, Viola Gleitsmann, Bernhard Moser, Bastian Hoesel, Bianca E. Suur, Florian Puhm, Caroline Ungerböck, Mario Kuttke, Maria J. Forteza, Christoph J. Binder, Daniel F.J. Ketelhuth, Alice Assinger, Johannes A. Schmid. Ikk2-mediated inflammatory activation of arterial endothelial cells promotes the development and progression of atherosclerosis. Atherosclerosis 2020; 307 doi: 10.1016/j.atherosclerosis.2020.06.005
|
| 173 |
Andrew S. Bell, Josephin Wagner, Daniel B. Rosoff, Falk W. Lohoff. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system. Neuroscience & Biobehavioral Reviews 2023; 149 doi: 10.1016/j.neubiorev.2023.105155
|
| 174 |
Bijay Mukesh Jeswani, Shubhangi Sharma, Sawai Singh Rathore, Abubakar Nazir, Rohit Bhatheja, Kapil Kapoor. PCSK9 Inhibitors: The Evolving Future. Health Science Reports 2024; 7(11) doi: 10.1002/hsr2.70174
|
| 175 |
Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Eeshal Fatima, Faryal Altaf, Timothy J. Vittorio. Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies. Annals of Medicine & Surgery 2024; 86(5) doi: 10.1097/MS9.0000000000001945
|
| 176 |
Matthew Perry Koppinger, Marissa Anne Lopez-Pier, Rinku Skaria, Preston Royal Harris, John P. Konhilas. Lactobacillus reuteri attenuates cardiac injury without lowering cholesterol in low-density lipoprotein receptor-deficient mice fed standard chow. American Journal of Physiology-Heart and Circulatory Physiology 2020; 319(1) doi: 10.1152/ajpheart.00569.2019
|
| 177 |
Mitali Paryani, Nikita Gupta, Sanjay Kumar Jain, Shital Butani. Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies. Naunyn-Schmiedeberg's Archives of Pharmacology 2025; 398(6) doi: 10.1007/s00210-025-03826-4
|
| 178 |
Sylwester Rogula, Ewelina Błażejowska, Aleksandra Gąsecka, Łukasz Szarpak, Milosz J. Jaguszewski, Tomasz Mazurek, Krzysztof J. Filipiak. Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis. Journal of Clinical Medicine 2021; 10(11) doi: 10.3390/jcm10112467
|
| 179 |
Abdallah Elshafeey. Therapeutic Management of LDL-C: Efficacy and Economic Impact Assessment. Journal of Cardiovascular Development and Disease 2025; 12(5) doi: 10.3390/jcdd12050196
|
| 180 |
Heidi M. Schmidt, Kelsey E. Jarrett, Thomas Q. de Aguiar Vallim, Elizabeth J. Tarling. Pathways and Molecular Mechanisms Governing LDL Receptor Regulation. Circulation Research 2025; 136(8) doi: 10.1161/CIRCRESAHA.124.323578
|
| 181 |
Letong Hong, Shuting Xia, Niankun Chen, Zilian Wang, Zhuyu Li. Quercetin’s regulation of glucose and lipid metabolism in gestational diabetes mellitus: role of the PCSK9/LDLR axis. Nutrition & Metabolism 2025; 22(1) doi: 10.1186/s12986-025-01048-2
|
| 182 |
Nikita Deo, Halima Siddiqui, Katie Peppercorn, Golnoush Madani, Alexandria Rutherford-Blyth, Malcolm Rutledge, Michael J.A. Williams, Sally P.A. McCormick, Gregory M.I. Redpath. Antidepressants stimulate lipoprotein(a) macropinocytosis via serotonin-enhanced cell surface binding. Journal of Lipid Research 2025; 66(10) doi: 10.1016/j.jlr.2025.100889
|
| 183 |
Valentina Rodriguez, Jonathan D. Newman, Arthur Z. Schwartzbard. Towards more specific treatment for diabetic dyslipidemia. Current Opinion in Lipidology 2018; 29(4) doi: 10.1097/MOL.0000000000000528
|
| 184 |
Alfonso Soler-Bistué, Angeles Zorreguieta, Marcelo E. Tolmasky. Bridged Nucleic Acids Reloaded. Molecules 2019; 24(12) doi: 10.3390/molecules24122297
|
| 185 |
Guangwei Huang, Xiyang Lu, Haiyan Zhou, Runhong Li, Qing Huang, Xinlin Xiong, Zhenhua Luo, Wei Li. PCSK9 inhibition protects against myocardial ischemia-reperfusion injury via suppressing autophagy. Microvascular Research 2022; 142 doi: 10.1016/j.mvr.2022.104371
|
| 186 |
Arrigo F.G. Cicero, Maryam Mahjoubin-Tehran, Željko Reiner, Ali H. Eid, Tannaz Jamialahmadi, Amirhossein Sahebkar. From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapies. Pharmacological Reviews 2026; 78(2) doi: 10.1016/j.pharmr.2025.100110
|
| 187 |
Amino Acid Conjugates of 2-Mercaptobenzimidazole Ameliorates High-Fat Diet-Induced Hyperlipidemia in Rats via Attenuation of HMGCR, APOB, and PCSK9. ACS Omega 2022; 7(44) doi: 10.1021/acsomega.2c05735
|
| 188 |
Mubashir Zafar. Exploring the Association of Lipid-Lowering Drugs with Diabetes: A Comprehensive Review. Trends in Medical Research 2024; 19(1) doi: 10.3923/tmr.2024.86.91
|
| 189 |
Amit Rout, Ajaypaul Sukhi, Rahul Chaudhary, Kevin P Bliden, Udaya S Tantry, Paul A Gurbel. Investigational drugs in phase II clinical trials for acute coronary syndromes. Expert Opinion on Investigational Drugs 2020; 29(1) doi: 10.1080/13543784.2020.1708324
|
| 190 |
Victoria Harbour, Candice Casillas, Zain Siddiqui, Biplab Sarkar, Sreya Sanyal, Peter Nguyen, Ka Kyung Kim, Abhishek Roy, Patricia Iglesias-Montoro, Saloni Patel, Frank Podlaski, Peter Tolias, William Windsor, Vivek Kumar. Regulation of Lipoprotein Homeostasis by Self-Assembling Peptides. ACS Applied Bio Materials 2020; 3(12) doi: 10.1021/acsabm.0c01229
|
| 191 |
Ramyashree Tummala, Manasvi Gupta, Arvind Reddy Devanabanda, Dhrubajyoti Bandyopadhyay, Wilbert S. Aronow, Kausik K. Ray, Mamas Mamas, Raktim K. Ghosh. Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis. Annals of Medicine 2022; 54(1) doi: 10.1080/07853890.2022.2059559
|
| 192 |
Marios Papasotiriou, Theodoros Ntrinias, Eirini Savvidaki, Evangelos Papachristou, Dimitrios S. Goumenos. Treatment of Mixed Dyslipidemia With Alirocumab in a Kidney Transplant Recipient: A Case Report. Transplantation Proceedings 2021; 53(9) doi: 10.1016/j.transproceed.2021.08.027
|
| 193 |
Carrie Palmer. New Directions in Managing Dyslipidemia. The Journal for Nurse Practitioners 2019; 15(1) doi: 10.1016/j.nurpra.2018.08.033
|
| 194 |
Amber Carelse, Helgard M Rossouw, Nicolene Steyn, Janine Martins, Tahir S Pillay. Calculated LDL-cholesterol: comparability of the extended Martin/Hopkins, Sampson/NIH, Friedewald and four other equations in South African patients. Journal of Clinical Pathology 2024; 77(10) doi: 10.1136/jcp-2023-208916
|
| 195 |
Daniel B. Rosoff, Andrew S. Bell, Jeesun Jung, Josephin Wagner, Lucas A. Mavromatis, Falk W. Lohoff. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function. Journal of the American College of Cardiology 2022; 80(7) doi: 10.1016/j.jacc.2022.05.041
|
| 196 |
Zhu Luo, Zhijun Huang, Feng Sun, Fang Guo, Yingying Wang, Sheena Kao, Guoping Yang, Jie Huang, Jiaxin Li, Sylvia Zhao, YanLing He. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Journal of Clinical Lipidology 2023; 17(3) doi: 10.1016/j.jacl.2023.04.010
|
| 197 |
Omonzejie E. Imaralu, Chandrakala Aluganti Narasimhulu, Pawan K. Singal, Dinender K. Singla. Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications. Canadian Journal of Physiology and Pharmacology 2024; 102(01) doi: 10.1139/cjpp-2023-0223
|
| 198 |
Adrianna Dec, Aleksandra Niemiec, Eliza Wojciechowska, Mateusz Maligłówka, Łukasz Bułdak, Aleksandra Bołdys, Bogusław Okopień. Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy. International Journal of Molecular Sciences 2023; 24(7) doi: 10.3390/ijms24076858
|
| 199 |
Gurpreet Kaur Batra, Chakrant Mothsara, Swati Sharma, Aishwarya Anand, Alka Bhatia, Shobhit Bhansali, Sant Ram, Arnab Pal, Amol N. Patil. Dose–Response Evaluation of Scopoletin, a Phytochemical, in a High-Fructose High-Fat Diet-Induced Dyslipidemia Model in Wistar Rats. Journal of Medicinal Food 2023; 26(5) doi: 10.1089/jmf.2022.K.0120
|
| 200 |
Chukwuemezie Kamanu, Dean G. Karalis. The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention. Current Atherosclerosis Reports 2025; 27(1) doi: 10.1007/s11883-025-01283-1
|
| 201 |
Candace L. Jackson, Yihong Deng, Xiaoxi Yao, Holly Van Houten, Nilay D. Shah, Stephen Kopecky. Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia. Journal of Clinical Lipidology 2021; 15(2) doi: 10.1016/j.jacl.2020.12.009
|
| 202 |
Chanisa Thonusin, Patcharapong Pantiya, Thidarat Jaiwongkam, Sasiwan Kerdphoo, Busarin Arunsak, Patchareeya Amput, Siripong Palee, Wasana Pratchayasakul, Nipon Chattipakorn, Siriporn C. Chattipakorn. A proprotein convertase subtilisin/kexin type 9 inhibitor provides comparable efficacy with lower detriment than statins on mitochondria of oxidative muscle of obese estrogen-deprived rats. Menopause 2020; 27(10) doi: 10.1097/GME.0000000000001586
|
| 203 |
Ioannis D. Karantas, Mehmet E. Okur, Neslihan Ü. Okur, Panoraia I. Siafaka. Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21(5) doi: 10.2174/1871530320666200810144004
|
| 204 |
Tao Cai, Nashmi Naife Al-Jubairi, Heitor O. Santos, Ivan G.O. de Souza, Youdong Chen. Does letrozole treatment have favorable effects on the lipid profile? A systematic review and meta-analysis of randomized clinical trials. Steroids 2021; 172 doi: 10.1016/j.steroids.2021.108875
|
| 205 |
Mojgan Nejabat, Farzin Hadizadeh, Wael Almahmeed, Amirhossein Sahebkar. Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases. Drug Discovery Today 2025; 30(3) doi: 10.1016/j.drudis.2025.104316
|
| 206 |
Rajeev Chawla, S. V. Madhu, B. M. Makkar, Sujoy Ghosh, Banshi Saboo, Sanjay Kalra. RSSDI-ESI Clinical Practice Recommendations for the Management
of Type 2 Diabetes Mellitus 2020. International Journal of Diabetes in Developing Countries 2020; 40(S1) doi: 10.1007/s13410-020-00819-2
|
| 207 |
Ikponmwosa Jude Ogieuhi, Kristen Callender, God-dowell O. Odukudu, Emeka Stanley Obi, Kudzaishe Muzofa, Adetola Emmanuel Babalola, Oshomoh Mark-Anthony Ugiomoh, Kenechukwu Hilary Umenzeakor, Adewunmi Akingbola, Charity Onetemizeh Ayoson, Emmanuel Uchenna Agbo, Moses Chukwuebuka Odoeke. Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials. High Blood Pressure & Cardiovascular Prevention 2024; 32(1) doi: 10.1007/s40292-024-00682-w
|
| 208 |
Angela Lee, Sunny Wei, Adel Schwertani. A Notch more: Molecular players in bicuspid aortic valve disease. Journal of Molecular and Cellular Cardiology 2019; 134 doi: 10.1016/j.yjmcc.2019.05.018
|
| 209 |
George Valeriu Moldovan, Adina Huțanu, Liliana Demian, Laszlo Hadadi, Bogdan Mănescu, Minodora Dobreanu. The utility of MLPA in Familial Hypercholesterolemia diagnosis. Acta Marisiensis - Seria Medica 2021; 67(3) doi: 10.2478/amma-2021-0021
|
| 210 |
Aida Collado, Elena Domingo, Laura Piqueras, Maria-Jesus Sanz. Primary hypercholesterolemia and development of cardiovascular disorders: Cellular and molecular mechanisms involved in low-grade systemic inflammation and endothelial dysfunction. The International Journal of Biochemistry & Cell Biology 2021; 139 doi: 10.1016/j.biocel.2021.106066
|
| 211 |
Ada Cuevas, Rodrigo Alonso. Bempedoic acid: A new player in lipid-lowering therapies. Journal of Clinical Lipidology 2020; 14(5) doi: 10.1016/j.jacl.2020.08.014
|
| 212 |
Ricardo Fontes‐Carvalho, Pedro Marques Silva, Elisabete Rodrigues, Francisco Araújo, Cristina Gavina, Jorge Ferreira, João Morais. Guia prático para a utilização dos inibidores da PCSK9 em Portugal. Revista Portuguesa de Cardiologia 2019; 38(6) doi: 10.1016/j.repc.2019.05.005
|
| 213 |
Bhavani Shankara Bagepally, Akhil Sasidharan. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. European Journal of Clinical Pharmacology 2022; 78(3) doi: 10.1007/s00228-021-03242-6
|
| 214 |
Dominic Mitchell, Jason R. Guertin, Jacques LeLorier. Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. Molecular Diagnosis & Therapy 2018; 22(6) doi: 10.1007/s40291-018-0356-6
|
| 215 |
Hongju Liu, Huiyi Xie, Changqun Li, Lingling Wang, Qiling Chen, Xin Ouyang, Chong Yan. Diaporisoindole B Reduces Lipid Accumulation in THP-1 Macrophage Cells via MAPKs and PPARγ–LXRα Pathways and Promotes the Reverse Cholesterol Transport by Upregulating SR-B1 and LDLR in HepG2 Cells. Journal of Natural Products 2022; 85(12) doi: 10.1021/acs.jnatprod.2c00715
|
| 216 |
Jianqiang Li, Carlotta Bollati, Martina Bartolomei, Angelica Mazzolari, Anna Arnoldi, Giulio Vistoli, Carmen Lammi. Hempseed (Cannabis sativa) Peptide H3 (IGFLIIWV) Exerts Cholesterol-Lowering Effects in Human Hepatic Cell Line. Nutrients 2022; 14(9) doi: 10.3390/nu14091804
|
| 217 |
Hong Lin, Juan I. Luengo. Exploiting binding-site arginines in drug design: Recent examples. Bioorganic & Medicinal Chemistry Letters 2020; 30(19) doi: 10.1016/j.bmcl.2020.127442
|
| 218 |
S. K. Zyryanov, O. I. Butranova. New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy. Russian Journal of Cardiology 2022; 27(11) doi: 10.15829/1560-4071-2022-5271
|
| 219 |
Sanjana Jagannath, Nandini D. Chilkunda. High cholesterol-supplemented diet during gestation and lactation alters liver glycosaminoglycans and associated lipoprotein receptors and results in fat accumulation in adulthood. Nutrition Research 2021; 93 doi: 10.1016/j.nutres.2021.07.002
|
| 220 |
Grigoris Thermos, Konstantinos I. Tosios. Gingival Ischemia and Petechiae in a Patient Medicated With PCSK9 Inhibitor for Hypercholesterolemia: An Adverse Drug Event?. Clinical Advances in Periodontics 2019; 9(1) doi: 10.1002/cap.10043
|
| 221 |
Semira Abdi Beshir, Nadia Hussain, Asim Ahmed Elnor, Amira S. A. Said. Umbrella Review on Non-Statin Lipid-Lowering Therapy. Journal of Cardiovascular Pharmacology and Therapeutics 2021; 26(5) doi: 10.1177/10742484211002943
|
| 222 |
Ji Liu, Jin Chang, Ying Jiang, Xiandi Meng, Tianmeng Sun, Lanqun Mao, Qiaobing Xu, Ming Wang. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles. Advanced Materials 2019; 31(33) doi: 10.1002/adma.201902575
|
| 223 |
Hasan Faisal Shehab, Rajesh Rajan, Mohammed Al Jarallah, Raja Dashti, Ahmad AlSarraf, Ahmad Al-Saber, Gary Tse, Laura AlObaid, Peter Lansberg. Impact of Proprotein Convertase Subtilisin/Kexin-9 Inhibitors on Low-density Lipoprotein Cholesterol and Nonhigh-density Lipoprotein Cholesterol Stratified by Sex: A Real-world Analysis in a Kuwaiti Population. Annals of Clinical Cardiology 2025; 7(1) doi: 10.4103/ACCJ.ACCJ_28_24
|
| 224 |
Antidyslipidaemic effect of Ipomoea batatas L. extract with increased PCSK-9 levels in atherosclerotic rats. Indonesian Journal of Medical Laboratory Science and Technology 2026; 8(1) doi: 10.33086/ijmlst.v8i1.7260
|
| 225 |
Roohollah Sattari, Abbasali Palizban, Hossein Khanahmad. Single-Strand DNA-Like Oligonucleotide Aptamer Against Proprotein Convertase Subtilisin/Kexin 9 Using CE-SELEX: PCSK9 Targeting Selection. Cardiovascular Drugs and Therapy 2020; 34(4) doi: 10.1007/s10557-020-06986-y
|
| 226 |
Hui-Hui Liu, Sha Li, Jian-Jun Li. A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1800502
|
| 227 |
Majed S Alqahtani , Khalid F Alzibali, Abdulaziz Mahdi M Mahdi, Osama Mohammed A Alharbi , Reem Hafiz A Harbi , Hamad Saad M Alkhaldi, Zahrah Ali A Alsayafi, Fatema H Albisher, Murtadha H Buqurayn, Meshal M Alharbi . Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review. Cureus 2024; doi: 10.7759/cureus.65202
|
| 228 |
Mario Peña-Peña, Óscar Zepeda-García, Rosalinda Posadas-Sánchez, Fausto Sánchez-Muñoz, Mayra Domínguez-Pérez, Juan Alfonso Martínez-Greene, Fabiola López-Bautista, Adrián Hernández-Díazcouder, Rogelio F. Jiménez-Ortega, Alejandra Idan Valencia-Cruz, Adrián Nuñez-Salgado, Isaac Emanuel Mani-Arellano, Karina Martínez-Flores, Teresa Villarreal-Molina, Eduardo Martínez-Martínez, Leonor Jacobo-Albavera. A Plasma Extracellular Vesicle-Derived microRNA Signature as a Potential Biomarker for Subclinical Coronary Atherosclerosis. International Journal of Molecular Sciences 2025; 26(17) doi: 10.3390/ijms26178727
|
| 229 |
Pierre Giguère, Salin Nhean, Alice L. Tseng, Christine A. Hughes, Jonathan B. Angel. Getting to the Heart of the Matter: A Review of Drug Interactions Between HIV Antiretrovirals and Cardiology Medications. Canadian Journal of Cardiology 2019; 35(3) doi: 10.1016/j.cjca.2018.12.020
|
| 230 |
Dongdong Wang, Yang Yang, Yingnan Lei, Nikolay T. Tzvetkov, Xingde Liu, Andy Wai Kan Yeung, Suowen Xu, Atanas G. Atanasov. Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products. Pharmacological Reviews 2019; 71(4) doi: 10.1124/pr.118.017178
|
| 231 |
Alexander D. Mazura, Anke Ohler, Steffen E. Storck, Magdalena Kurtyka, Franka Scharfenberg, Sascha Weggen, Christoph Becker-Pauly, Claus U. Pietrzik. PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier. Cellular and Molecular Life Sciences 2022; 79(4) doi: 10.1007/s00018-022-04237-x
|
| 232 |
Arcangelo Iannuzzi, Paolo Rubba, Marco Gentile, Vania Mallardo, Ilenia Calcaterra, Alessandro Bresciani, Giuseppe Covetti, Gianluigi Cuomo, Pasquale Merone, Anna Di Lorenzo, Roberta Alfieri, Emilio Aliberti, Francesco Giallauria, Matteo Nicola Dario Di Minno, Gabriella Iannuzzo. Carotid Atherosclerosis, Ultrasound and Lipoproteins. Biomedicines 2021; 9(5) doi: 10.3390/biomedicines9050521
|
| 233 |
Amy S. Etheridge, Paul J. Gallins, Dereje Jima, K. Alaine Broadaway, Mark J. Ratain, Erin Schuetz, Eric Schadt, Adrian Schroder, Cliona Molony, Yihui Zhou, Karen L. Mohlke, Fred A. Wright, Federico Innocenti. A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex‐Biased Phenotypes. Clinical Pharmacology & Therapeutics 2020; 107(6) doi: 10.1002/cpt.1751
|
| 234 |
Maria Lorenzi, Baishali Ambegaonkar, Carl A. Baxter, Jeroen Jansen, Michael J. Zoratti, Glenn Davies. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clinical Research in Cardiology 2019; 108(5) doi: 10.1007/s00392-018-1379-z
|
| 235 |
Yang Yang, Yeying Wang, Yuwen Wang, Tingyu Ke, Ling Zhao. PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model. PeerJ 2024; 12 doi: 10.7717/peerj.17676
|
| 236 |
Swapnil Raj, Liston Augustine Dsouza, Shailendra Pratap Singh, Abhinav Kanwal. Sirt6 Deacetylase: A Potential Key Regulator in the Prevention of Obesity, Diabetes and Neurodegenerative Disease. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.598326
|
| 237 |
Taher A. Salaheldin, Kavitha Godugu, Dhruba J. Bharali, Kazutoshi Fujioka, Nabil Elshourbagy, Shaker A. Mousa. Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia. Nanomedicine: Nanotechnology, Biology and Medicine 2022; 40 doi: 10.1016/j.nano.2021.102480
|
| 238 |
Brian Hon Yin Chung, Jeffrey Fong Ting Chau, Gane Ka-Shu Wong. Rare versus common diseases: a false dichotomy in precision medicine. npj Genomic Medicine 2021; 6(1) doi: 10.1038/s41525-021-00176-x
|
| 239 |
Thomas Duflot, Ly Tu, Matthieu Leuillier, Hind Messaoudi, Déborah Groussard, Guillaume Feugray, Saïda Azhar, Raphaël Thuillet, Fabrice Bauer, Marc Humbert, Vincent Richard, Christophe Guignabert, Jérémy Bellien. Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?. Metabolites 2021; 11(11) doi: 10.3390/metabo11110784
|
| 240 |
Zhixin Ma, Hongtao Liu, Shan Jiang, Wenya Li, Yue Li, Yiting Liu, Li Wang, Wenyan Li. Identification of benzothiazoles as novel PCSK9 inhibitors. Bioorganic & Medicinal Chemistry Letters 2024; 97 doi: 10.1016/j.bmcl.2023.129542
|
| 241 |
María Jesús Valero, Carlos Ortiz-Bautista, Javier Gonzalez-Martín, Raquel López-Vilella, Clara Simón-Ramon, Andrés Fernando Barragán-Amado, Francisco Carrasco, María del Val Groba-Marco, Elena García-Romero, Javier Castrodeza, Zorba Blázquez, Iago Sousa, Javier Bermejo, Manuel Martínez-Sellés. PCSK9 Inhibitors in Heart Transplant Recipients. Transplantation Proceedings 2026; doi: 10.1016/j.transproceed.2026.04.035
|
| 242 |
Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis, Christos Mantzoros. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism 2017; 74 doi: 10.1016/j.metabol.2017.04.007
|
| 243 |
Si Cheng, Zhe Xu, Shengzhe Bian, Xi Chen, Yanfeng Shi, Yanran Li, Yunyun Duan, Yang Liu, Jinxi Lin, Yong Jiang, Jing Jing, Zixiao Li, Yilong Wang, Xia Meng, Yaou Liu, Mingyan Fang, Xin Jin, Xun Xu, Jian Wang, Chaolong Wang, Hao Li, Siyang Liu, Yongjun Wang. The STROMICS genome study: deep whole-genome sequencing and analysis of 10K Chinese patients with ischemic stroke reveal complex genetic and phenotypic interplay. Cell Discovery 2023; 9(1) doi: 10.1038/s41421-023-00582-8
|